- UroToday Home
- Urologic Oncology
Prostate Cancer Abstracts and Beyond
Recent Abstracts
-
Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.Prostate CancerNovember 1, 2024
-
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.Prostate CancerNovember 1, 2024
-
Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.Prostate CancerNovember 1, 2024
-
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617.Prostate CancerNovember 1, 2024
-
PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases.Prostate CancerNovember 1, 2024
-
Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.Prostate CancerNovember 1, 2024
-
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database.Prostate CancerOctober 31, 2024
-
Incidence and mortality of prostate cancer in France from 2010 to 2021, using a real-life database (National Health Data System - SNDS) - the CaPCo Study.Prostate CancerOctober 31, 2024
-
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-WProstate CancerOctober 31, 2024
-
Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy.Prostate CancerOctober 31, 2024
Beyond the Abstracts
-
A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy - Beyond the AbstractProstate CancerOctober 31, 2024
-
How Can Participant Experience of Quality-of-Life Research Be Improved in Cancer Research: Views of the Patient and Public Involvement Representatives from the STAMPEDE2 Prostate Cancer Trial - Beyond the AbstractProstate CancerOctober 22, 2024
-
Sequential [177Lu]Lu-PSMA-617 and Docetaxel Versus Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer (UpFrontPSMA): A Multicentre, Open-Label, Randomised, Phase 2 Study - Beyond the AbstractProstate CancerOctober 22, 2024
-
Prostate Cancer Early Detection in the European Union and UK - Beyond the AbstractProstate CancerOctober 18, 2024
-
Local Salvage Therapies in Patients with Radio-Recurrent Prostate Cancer Following External Beam Radiotherapy: A Systematic Review and Meta-Analysis - Beyond the AbstractProstate CancerOctober 18, 2024
-
A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease - Beyond the AbstractProstate CancerOctober 18, 2024
-
Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management - Beyond the AbstractProstate CancerOctober 17, 2024
-
Prediction of Undetectable Circulating Tumor DNA by Comprehensive Genomic Profiling Assay in Metastatic Prostate Cancer: The SCRUM-Japan MONSTAR SCREEN Project - Beyond the AbstractProstate CancerOctober 16, 2024
-
Survival of Men with Metastatic Hormone-Sensitive Prostate Cancer and Adrenal-Permissive HSD3B1 Inheritance - Beyond the AbstractProstate CancerOctober 15, 2024
-
Multiplex Imaging of Localized Prostate Tumors Reveals Altered Spatial Organization of AR-Positive Cells in the Microenvironment - Beyond the AbstractProstate CancerOctober 9, 2024